According to the “Schedule” portion of the contract/agreement:
There are currently no medical countermeasures available for the prophylaxis or treatment of infection with Ebola virus, a high priority agent for the Public Health Emergency medical Countermeasures Enterprise (PHEMCE) Implementation Plan.
An effective prophylactic vaccine would find application with medical personnel and close contacts during outbreaks in endemic areas of sub-Saharan Africa, with laboratory workers engaged in filovirus research, and with military and civilian personnel threatened by weaponized filoviruses. The ideal vaccine to meet both the outbreak and bio-weapon scenarios would rapidly confer protection with a single administration.
Pre-clinical studies conducted by Profectus in collaboration with other laboratories have investigated an rVSVN4CT1 vectored vaccine encoding the surface glycoprotein (GP) of Zaire-EboV (rVSVN4CT1-Z- EbovGP). This rVSV vaccine is based on the bullet shaped Rhadovirus, vesicular stomatitis virus. The virus is a negative-strand, non-segmented RNA virus that has been modified to enable the delivery of immunogens. There is little pre-existing immunity in humans and the vectors can be engineered to express the surface glycoproteins of targeted viruses into the envelope of the VSV. The Profectus rVSV vaccine has demonstrated single dose protection in Guinea Pigs and NHPs against lethal challenge with Ebola and Marburg viruses. Profectus has shown safety of its rVSV platform in human studies of its rVSV-vectored HIV vaccine, which has completed 2 clinical trials in which safety, vaccine take, and immunogenicity across a range of doses was demonstrated.
This contract will support the advancement of the monovalent rVSVN4CT1 Ebola Zaire vaccine through preparation of an IND application for a Phase I clinical trial. These IND enabling activities include re-derivation of the recombinant vaccine under compliant conditions; a pre-IND meeting with the FDA to obtain feedback on the proposed path forward (specifically toxicology requirements); generation of immune serum from rabbits to neutralize vaccine during testing for adventitious agents; manufacture the monovalent vaccine under GMP conditions; toxicology testing and assays to support clinical evaluation.
The Advanced Research and Development effort will progress in specific stages that cover the base work segment and six (6) option work segments, as specified in this contract. The estimated period of performance for the base period is twelve (12) months. The work to be performed during the base segment represents a non-severable discrete work segment. Each of the option work segment represents further represents a non-severable discrete work segment. The work in the base segment and each option segment will be fully funded from funds that are available for obligation at the time of the initial award (Base segment) and at the time of the award of each option segment.
https://documents.theblackvault.com/documents/dhhs/2015-0077.pdf
Follow The Black Vault on Social Media:This post was published on February 15, 2018 6:07 am
In September 2024, a Freedom of Information Act (FOIA) request was filed with NASA seeking…
Background Welcome to the FBI Files on Historical Figures & Groups archive at The Black…
A new release of Department of Defense (DoD) emails obtained through the Freedom of Information…
Newly released Department of Defense records reveal the prolonged and often frustrating prepublication review process…
Newly released Federal Aviation Administration (FAA) documents obtained by The Black Vault under FOIA case…
Background The Central Intelligence Agency was created in 1947 with the signing of the National…